The dopaminergic system in peripheral blood lymphocytes: From physiology to pharmacology and potential applications to neuropsychiatric disorders

Current Neuropharmacology

Volumn 9, Issue 2, 2011, Pages 278-288

  Buttarelli, Francesca R ^a   Fanciulli, Alessandra ^a,b   Pellicano, Clelia ^a,b   Pontieri, Francesco E ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dopamine; Dopamine receptors; Dopamine transporter; Neuropsychiatric disorders; Peripheral blood lymphocytes

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DIAMORPHINE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA; LOXAPINE; MESSENGER RNA; METHADONE; NEUROLEPTIC AGENT; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

ALCOHOL ABUSE; ALCOHOL WITHDRAWAL; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG ABUSE; ELECTROCHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; GILLES DE LA TOURETTE SYNDROME; HEROIN DEPENDENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOREGULATION; MENTAL DISEASE; MIGRAINE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PERIPHERAL LYMPHOCYTE; PHYSIOLOGY; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SHY DRAGER SYNDROME; T LYMPHOCYTE; TUMOR GROWTH; WILSON DISEASE;

EID: 79958167848     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911795596612     Document Type: Article

References (110)

1. Kandel, E.R.; Schwartz, J.H.; Jessel, T.M. Principles of Neural Science; McGraw-Hill: New York, 2000.
2. Medina, L., Reiner, A. Neurotransmitter organization and connectivity of the basal ganglia in vertebrates: implications for the evolution of basal ganglia. Brain Behav. Evol., 1995, 46, 253-258.
3. Palkovits, M. Topography of chemically identified neurons in the central nervous system: progress in 1977-1979. Med. Biol., 1980, 58, 188-227.
4. Cave, J.W., Baker, H. Dopamine systems in the forebrain. Adv. Exp. Med. Biol., 2009, 651, 15-35.
5. Porter, J.C., Kedzierski, W, Aguila-Mansilla, N., Jorquera, B.A., Gonzales, H.A. The tuberoinfundibular dopaminergic neurons of the brain: hormonal regulation. Adv. Exp. Med. Biol., 1990, 274, 1-23.
6. Sibley, D.R., Monsma, F.J. Molecular biology of dopamine receptors. Trends Pharm. Sci., 1992, 13, 61-69.
7. Civelli, O., Bunzow, J.R., Grandy, D.K., Zhou, Q.Y., Van Tol, H.M.M. Molecular biology of the dopamine receptors. Eur. J. Pharmacol., 1991, 207, 277-286.
8. Strange, P.G. New insight into dopamine receptors in the central nervous system. Neurochem. Int., 1993, 22, 223-236.
9. Nagatsua, T., Sawadab, M. L-Dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat. Disord., 2009, 15(suppl. 1), S3-S8.
10. Giros, B., El Mestikawy, S., Bertrand, L., Caron, M.G. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett., 1991, 295, 149-154.
11. Masson, J., Sagnè, C., Hamon, M, El Mestikawy, S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev., 1999, 51, 439-464.
12. Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol. Neurosurg. Psychiatry, 1992, 55, 181-185.
13. Torta, D.M., Castelli, L. Reward pathways in Parkinson's disease: clinical and theoretical implications. Psychiatry Clin. Neurosci., 2008, 62, 203-213.
14. 123Iiodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur. Neurol., 2008, 59, 258-266.
15. Scherfler, C., Schwarz, J., Antonini, A., Grosset, D., Valldeoriola, F., Marek, K., Oertel, W., Tolosa, E., Lees, A.J., Poewe, W. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov. Disord., 2007, 22, 1229-1238.
16. 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 556-564.
17. Bruggeman, R., Van der Linden, C., Buitelaar, J.K., Gericke, G.S., Hawkridge, S.M., Temlett, J.A. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin. Psychiatry, 2001, 62, 50-56.
18. Singer, H.S., Szymanski, S., Giuliano, J., Yokoi, F., Dogan, A.S., Brasic, J.R., Zhou, Y., Grace, A.A., Wong, D.F. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am. J. Psychiatry, 2002, 159, 1329-1336.
19. Francis, P.T., Palmer, A.M., Snape, M., Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry, 1999, 66, 137-147.
20. Bondareff, W., Mountjoy, C.Q., Roth, M., Rossor, M.N., Iversen, L.L., Reynolds, G.P., Hauser, D.L. Neuronal degeneration in locus coeruleus and cortical correlates of Alzheimer's disease. Alzheimer's Dis. Assoc. Disord., 1987, 1, 256-262.
21. Reeves, S., Mehta, M., Howard, R., Grasby, P., Brown, R. The dopaminergic basis of cognitive and motor performance in Alzheimer's disease. Neurobiol. Dis., 2010, 37, 477-482.
22. Reeves, S., Brown, R., Howard, R., Grasby, P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology, 2009, 72, 528-534.
23. Cerbo, R., Barbanti, P., Buzzi, M.G. Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin. Neuropharmacol., 1997, 20, 36-41.
24. Del Zompo, M., Cherchi, A., Palmas, M.A., Ponti, M., Bocchetta, A., Gessa, G.L., Piccardi, M.P. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology, 1998, 51, 781-786.
25. Peroutka, S.J., Wilhoit, T., Jones, K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Neurology, 1997, 49, 201-206.
26. Janowsky, D.S., El-Yousel, M.K., Davis, J.M., Sekerke, H.J. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch. Gen. Psychiatry, 1973, 28, 185-191.
27. Matthysse, S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia. Federation Proc., 1973, 32, 200-208.
28. Pontieri, F.E., Tanda, G., Di Chiara, G. Intravenous cocaine, morphine and amphetamine preferentially increase extracellular dopamine in the "shell" as compared to the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. USA, 1995, 92, 12304-12308.
29. Pontieri, F.E., Tanda, G. Orzi, F., Di Chiara, G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 1996, 382, 255-257.
30. Tanda, G., Pontieri, F.E., Di Chiara, G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science, 1997, 276, 2048-2050.
31. Volkow, N.D., Fowler, J.S., Wang, G.J., Baler, R., Telang, F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology, 2009, 56(suppl. 1), 3-8.
32. Koob, G.F., Volkow, N.D. Neurocircuitry of addiction. Neuropsychopharmacology, 2010, 35, 217-238.
33. Mendels, J., Frazer, A., Fitzgerald, R.G., Ramsey, T.A., Stokes, J.W. Biogenic amine metabolites in the cerebrospinal fluid of depressed and manic patients. Science, 1972, 175, 1380-1382.
34. Banki, C.M. Correlation between CSF metabolites and psychomotor activity in affective disorders. J. Neurochem., 1977, 28, 255-257.
35. Mann, J.J., Kapur, S. A dopaminergic hypothesis of major depression. Clin. Neuropharmacol., 1995, 18(suppl. 1), S557-S567.
36. Cassano, P., Lattanzi, L., Soldani, F., Navari, S., Battistini, G., Gemignani, A., Cassano, G.B. Pramipexole in treatment-resistant depression: an extended follow-up. Depress. Anxiety, 2004, 20, 131-138.
37. Bergquist, J., Tarkowski, A., Ekman, R., Ewing, A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc. Natl. Acad. Sci. USA, 1994, 91, 12912-12916.
38. Bergquist, J., Silberring, J. Identification of catecholamines in the immune system by electrospray ionization mass spectroscopy. Rapid Commun. Mass Spectrom., 1998, 12, 683-688.
39. Musso, N.C., Brenci, S., Setti, M., Indiveri, F., Lotti, G. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. J. Clin. Endocrinol. Metab., 1996, 81, 3553-3557.
40. Qiu, Y.H., Pang, Y.P., Jiang, J.M., Wang, J.J. Expression of tyrosine hydroxylase in lymphocytes and effects of endogenous catecholamines on lymphocyte function. Neuroimmunomodulation, 2004, 11, 75-83.
41. Cosentino, M., Fietta, A.M., Ferrari, M., Rasini, E., Bombelli, R., Carcano, E., Saporiti, F., Meloni, F., Marino, F., Lecchini, S. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood, 2007, 109, 632-642.
42. Kikkonou, I., Nikolouzou, E., Hatzimanolis, A., Fragoulis, E.G., Vassilacopoulou, D. Expression of enzymatically active L-DOPA decarboxylase in human peripheral blood lymphocytes. Blood Cells Mol. Dis., 2009, 42, 92-98.
43. Maloteaux, J.M., Waterkein, C, Laduron, P.M. Absence of dopamine and muscarinic receptors on human lymphocytes. Arch. Int. Pharmacodyn. Ther., 1982, 258, 174-176.
44. Fleminger, S., Jenner, P., Marsden, C.D. Are dopamine receptors present on human lymphocytes? J. Pharm. Pharmacol., 1982, 34, 658-663.
45. 3H-spiperone to human peripheral lymphocytes: absence of stereospecific highaffinity binding. Psychiatry Res., 1989, 30, 259-264.
46. 2 receptors, in rat and human lymphocytes. Immunopharmacology, 1991, 22, 93-105.
47. 3H-spiroperidol binding to human peripheral mononuclear cells: metholodological aspects. Biol. Psychiatry, 1992, 31, 291-303.
48. Faraj, B.A., Olkowski, Z.L., Jackson, R.T. Binding of [3H]-dopamine to human lymphocytes: possible relationship to neurotransmitter uptake sites. Pharmacology, 1991, 42, 135-141.
49. Takahashi, N, Nagai, Y., Ueno, S., Saeki, Y., Yanagihara, T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett., 1992, 314, 23-25.
50. Nagai, Y., Ueno, S., Saeki, Y., Soga, F., Yanagihara, T. Expression of D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem. Biophys. Res. Commun., 1993, 194, 368-374.
51. Santambrogio, L., Lipartiti, M., Bruni, A., Dal Toso, R. Dopamine receptors on human T-and B-lymphocytes. J. Neuroimmunol., 1993, 45, 113-119.
52. Ricci, A., Amenta, F. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J. Neuroimmunol., 1994, 53, 1.7.
53. 3H]7-OH-DPAT. J. Neuroimmunol., 1995, 58, 139-144.
54. Barili, P., Bronzetti, E., Felici, L., Ferrante, F., Ricci, A., Zaccheo, D., Amenta, F. Age-dependent changes in the expression of dopamine receptor subtypes in human peripheral blood lymphocytes. J. Neuroimmunol., 1996, 71, 42-50.
55. Bondy, B., De Jonge, S., Pander, S., Primbs, J., Ackenheil, M. Identification of the dopamine D4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction. J. Neuroimmunol., 1996, 71, 139-144.
56. Ricci, A., Bronzetti, E., Felici, L., Tayebati, S.K., Amenta, F. Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci. Lett., 1997, 229, 130-134.
57. 3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study. J. Neuroimmunol., 1998, 92, 191-195.
58. Ricci, A., Bronzetti, E., Mignini, F., Tayebati, S.K., Zaccheo, D., Amenta, F. Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J. Neuroimmunol., 1999, 96, 234-240.
59. McKenna, F., McLaughlin, P.J., Lewis, B.J., Sibbring, G.C., Cummerson, J.A., Bowen-Jones, D., Moots, R.J. Dopamine receptor expression on human T-and B-lymphocytes, monocytes, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol., 2002, 132, 34-40.
60. Kirillova, G.P., Hrutkay, R.J., Shurin, M.R., Shurin, G.V., Tourkova, I.L., Vanyukov, M.M. Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J. Neurosci. Methods, 2008, 174, 272-280.
61. Amenta, F., Bronzetti, E., Cantalamessa, F., El-Assouad, D., Felici, L., Ricci, A., Tayebati, S.K. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J. Neuroimmunol., 2001, 117, 133-142.
62. Marazziti, D., Baroni, S., Catena Dell'Osso, M., Masala, I., Fabbrini, L., Betti, L., Giannaccini, D., Dell'Osso, B., Lucacchini, A. Presence and characterization of the dopamine transporter in human resting lymphocytes. Neurochem. Res., 2008, 33, 1011-1016.
63. Saha, B., Mondal, A.C., Majumder, J., Basu, S., Dasgupta, B.S. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a re ceptor-mediated mechanism. Neuroimmunomodulation, 2001, 9, 23-33.
64. Kipnis, J., Cardon, M., Avidan, H., Lewitus, G.M., Mordechay, S., Rolls, A., Shani, Y., Schwartz, M. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J. Neurosci., 2004, 24, 6133-6143.
65. Nakano, K., Higashi, T., Hashimoto, K., Takagi, R., Tanaka, Y., Matsushita, S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun., 2008, 373, 286-291.
66. Nakano, K., Higashi, T., Takagi, R., Hashimoto, K., Tanaka, Y., Matsushita, S. Dopamine released by dendritic cells polarizes Th2 differentiation. Int. Immunol., 2009, 21, 645-654.
67. Giorelli, M., Livrea, P., Trojano, M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J. Interferon Cytokine Res., 2005, 25, 395-406.
68. Besser, M.J., Ganor, Y., Levite, M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J. Neuroimmunol., 2005, 169, 161-171.
69. Buckley, A.F., Kuo, C.T., Leiden, J.M. Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc-dependent pathway. Nat. Immunol., 2001, 2, 698-704.
70. Sarkar, C., Das, S., Chakroborty, D., Chowdhury, U.R., Basu, B., Dasgupta, P.S., Basu, S. Cutting edge: stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J. Immunol., 2006, 177, 7525-7529.
71. Ilani, T., Strous, R.D., Fuchs, S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J., 2004, 18, 1600-1602.
72. Kivisakk, P., Trebst, C., Liu, Z., Tucky, B.H., Sorensen, T.L., Rudick, R.A., Mack, M., Ransohoff, R.M. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin. Exp. Immunol., 2002, 129, 510-518.
73. 3. J. Immunol., 2006, 176, 848-856.
74. 3H]spiroperidol binding sites in parkinsonism. Life Sci., 1980, 27, 1587-1591.
75. Maloteaux, J.M., Laterre, C.E., Hens, L., Laduron, P.M. Failure of a peripheral dopaminergic marker in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1983, 46, 1146-1148.
76. 3Hspiroperidol to lymphocyte in Wilson's disease. Acta Neurol. Scand., 1984, 69, 298-301.
77. 3H]spiperone binding to lymphocyte in extrapyramidal disease and aging. Brain Behav. Immun., 1987, 1, 197-203.
78. Nagai, Y., Ueno, S., Saeki, Y., Soga, F., Hirano, M., Yanagihara, T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology, 1996, 46, 791-795.
79. Barbanti, P., Fabbrini, G., Ricci, A., Cerbo, R., Bronzetti, E., Caronti, B., Calderaro, C., Felici, L., Stocchi, F., Meco, G., Amenta, F., Lenzi, G.L. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov. Disord., 1999, 14, 764-771.
80. Caronti, B., Tanda, G., Colosimo, C., Ruggieri, S., Calderaro, C., Palladini, G., Pontieri, F.E., Di Chiara, G. Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. Neuroreport, 1999, 10, 2907-2910.
81. Caronti, B., Antonini, G., Calderaro, C., Ruggieri, S., Palladini, G., Pontieri, F.E., Colosimo, C. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J. Neural Transm., 2001, 108, 803-807.
82. Pellicano, C., Buttarelli, F.R., Circella, A., Tiple, D., Giovannelli, M., Benincasa, D., Colosimo, C., Pontieri, F.E. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. J. Neural Transm., 2007, 114, 935-938.
83. Rajda, C, Dibò, G., Vécsei, L., Bergquist, J. Increased dopamine content in lymphocytes from high-dose L-dopa-treated Parkinson's disease patients. Neuroimmunomodulation, 2005, 12, 81-84.
84. Buttarelli, F.R., Capriotti, G., Pellicano, C., Prosperi, D., Circella, A., Festa, A., Giovannelli, M., Tofani, A., Pontieri, F.E., Scopinaro, F. Central and peripheral dopamine transporter reduction in Parkinson's disease. Neurol. Res., 2009, 31, 687-691.
85. Pontieri, F.E., Colosimo, C. Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease. Mov. Disord., 2010, 25, 125-126.
86. Buttarelli, F.R., Circella, A., Pellicano, C., Tiple, D., Giovannelli, M., Colosimo, C., Pontieri, F.E. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy. J. Neural Transm., 2009, 116, 161-165.
87. Buttarelli, F.R., Circella, A., Pellicano, C., Pontieri, F.E. Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis. Eur. J. Neurol., 2006, 13, 416-418.
88. Kato, S., Oda, M., Tanabe, H. Diminution of dopaminergic neurons in the substantia nigra of sporadic amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol., 1993, 19, 300-304.
89. Borasio, G.D., Linke, R, Schwarz, J., Schlamp, V., Abel, A., Mozley, P.D., Tatsch, K. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J. Neurol. Neurosurg. Psychiatry, 1998, 65, 263-265.
90. Ferrari, M., Termine, C., Franciotta, D., Castiglioni, E., Pagani, A., Lanzi, G., Marino, F., Lecchini, S., Cosentino, M., Balottin, U. Dopaminergic receptor D5 mRNA expression is increased in circulating lymphocytes of Tourette syndrome patients. J. Psychiatry Res., 2009, 43, 24-29.
91. Barbanti, P., Fabbrini, G., Ricci, A., Bruno, G., Cerbo, R., Bronzetti, E., Amenta, F., Lenzi, G.L. Reduced density of D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech. Ageing Dev., 2000, 120, 65-75.
92. Giubilei, F., Calderaro, C., Antonini, G., Sepe Monti, M., Tisei, P., Brunetti, E., Marchione, F., Caronti, B., Pontieri, F.E. Increased lymphocyte dopamine beta-hydroxylase immunoreactivity in Alzheimer's disease: compensatory response to cholinergic deficit? Dementia Geriatr. Cogn. Disord., 2004, 18, 338-341.
93. 5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine? Neurosci. Lett., 1996, 207, 73-76.
94. 4 receptors on lymphocytes. Cephalalgia, 2000, 20, 15-19.
95. 3Hspiperone to human lymphocytes: a biological marker of schizophrenia? Psychiatry Res., 1985, 15, 41-48.
96. 3H]spiperone by lymphocytes in schizophrenic patients and their first-degree relatives: a limited vulnerability marker? J. Psychiatr. Res., 1992, 26, 77-84.
97. Kwak, Y.T., Koo, M.S., Choi, C.H., Sunwoo I. Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients. BMC Med. Genet., 2001, 2, 3.
98. 3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. USA, 2001, 98, 625-628.
99. Singh, A.N., Barlas, C., Saeedi, H., Mishra, R.K. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia. J. Psychiatry Neurosci., 2003, 28, 39-47.
100. +-T cells. J. Neuroimmunol., 2006, 173, 180-187.
101. Vogel, M., Pfeifer, S., Schaub, R.T., Grabe, H.J., Barnow, S., Freyberger, H.J., Cascorbi, I. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology, 2004, 50, 305-310.
102. Marazziti, D., Catena Dell'Osso, M., Baroni, S., Masala, I., Dell'Osso, B., Consoli, G., Giannaccini, G., Betti, L., Lucacchini, A. Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders. Psychiatry Res., 2010, 175, 54-57.
103. Biermann, T., Bönsch, D., Reulbach, U., Kornhuber, J., Bleich, S. Dopamine and N-methyl-D-aspartate receptor expression in peripheral blood of patients undergoing alcohol withdrawal. J. Neural Transm., 2007, 114, 1081-1084.
104. Czermak, C., Lehofer, M., Wagner, E.M., Prietl, B., Lemonis, L., Rohrhofer, A., Schauenstein, K., Liebmann, P.M. Reduced dopamine D4 receptor mRNA expression in lymphocytes of long-term abstinent alcohol and heroin addicts. Addiction, 2004, 99, 251-257.
105. Goodarzi, A., Vousooghi, N., Sedaghati, M., Mokri, A., Zarrindast, M.R. Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction. Eur. J. Pharmacol., 2009, 615, 218-222.
106. Rocca, P., De Leo, C., Eva, C., Marchiaro, L., Milani, A.M., Musso, R., Ravizza, L., Zanalda, E., Bogetto, F. Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 2002, 26, 1155-1160.
107. 1A receptors and dopamine in blood peripheral lymphocytes of major depression patients. Int. Immunopharmacol., 2003, 3, 1345-1352.
108. Basu, S., Dasgupta, P.S. Role of dopamine in malignant tumor growth. Endocrine, 2000, 12, 237-241.
109. Cosentino, M., Zaffaroni, M., Ferrari, M., Marino, F., Bombelli, R., Rasini, E., Frigo, G., Ghezzi, A., Comi, G., Lecchini, S. Interferongamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis. J. Neuroimmunol., 2005, 162, 112-121.
110. Gordon, J., Barnes, N.M. Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol., 2003, 24, 438-443.